Thirty-Six Month Follow-up of 25 Patients Treated With Combination Anorganic Bovine-Derived Hydroxyapatite Matrix (ABM)/Cell-Binding Peptide (P-15) Bone Replacement Grafts in Human Infrabony Defects. I. Clinical Findings

• Autores: Dr. Raymond A. Yukna, Jack T. Krauser, Donald P. Callan, Gerald H. Evans, Renee Cruz, Millicent Martin
• Localización: Journal of periodontology, ISSN 0022-3492, Vol. 73, Nº. 1, 2002, págs. 123-128
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background: Long-term evaluation of periodontal therapy is important for clinical decision making.

    Methods: A synthetic cell-binding peptide (P-15) combined with anorganic bovine-derived hydroxyapatite bone matrix (ABM) was evaluated as a bone replacement graft in human periodontal osseous defects. Following initial preparation and reevaluation, flap surgery was performed. A variety of 1-, 2-, 3-wall bony defects were curetted and root surfaces subjected to mechanical debridement only. The bone defects were grafted with ABM/P-15, and the host flaps replaced or slightly coronally positioned. Weekly, then monthly deplaquing was performed until surgical reentry at 6 to 7 months. Patients were then followed on approximate 3-month recalls for 3 years. Twenty-five of the original 31 patients qualified for long-term evaluation in that their ABM/P-15 treated sites did not receive any additional therapy at the time of reentry.

    Results: Significant clinical changes for the overall group of bony defects included improvement in mean clinical attachment level from 5.4 mm at surgery to 4.5 mm at the 6-month reentry to 3.8 mm at 3 years. There was also a decrease in mean probing depth from 5.3 mm at surgery to 3.1 mm at the 6- month reentry to 2.9 mm at 3 years. The mean gingival recession changed from +0.1 mm at surgery to 1.4 mm at the 6-month reentry to 0.9 mm at 3 years. All of these differences were at least P <0.05 from surgery to the 6-month reentry, and surgery to 3 years, but were not significant from reentry to 3 years via repeated measures analysis of variance.

    Conclusions: These favorable 3-year results with ABM/P-15 suggest that it may have a beneficial effect in the long-term clinical management of infrabony defects. Further long-term randomized controlled studies are needed to better assess the role of ABM/P-15 in long-term healing of periodontal osseous defects.